Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Key Terms
sirnamedical
Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.
short interfering rnamedical
Short interfering RNA (siRNA) are tiny pieces of genetic material that act like a targeted mute button inside cells: they guide the cell’s natural molecular “scissors” to destroy the specific messages that tell a cell to make a particular protein. Investors care because siRNA can enable highly targeted medicines for diseases that are hard to treat with traditional drugs, but their commercial value depends on effective delivery, safety, manufacturing and regulatory approval.
webcasttechnical
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
LONDON--(BUSINESS WIRE)--
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET.
The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/
